SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
220.9 EUR
-1.9 (-0.85%)
Taking everything into account, 56S1 scores 4 out of 10 in our fundamental rating. 56S1 was compared to 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
56S1 had a positive operating cash flow in the past year.
Each year in the past 5 years 56S1 has been profitable.
Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
The Return On Assets of 56S1 (3.35%) is worse than 63.64% of its industry peers.
56S1 has a Return On Equity of 6.54%. This is comparable to the rest of the industry: 56S1 outperforms 40.91% of its industry peers.
56S1 has a Return On Invested Capital (5.94%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for 56S1 is in line with the industry average of 9.70%.
The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1 has a Profit Margin of 8.96%. This is comparable to the rest of the industry: 56S1 outperforms 54.55% of its industry peers.
In the last couple of years the Profit Margin of 56S1 has declined.
56S1 has a Operating Margin of 16.63%. This is in the better half of the industry: 56S1 outperforms 63.64% of its industry peers.
56S1's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 45.64%, 56S1 is in line with its industry, outperforming 54.55% of the companies in the same industry.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
Compared to 1 year ago, 56S1 has more shares outstanding
Compared to 5 years ago, 56S1 has more shares outstanding
Compared to 1 year ago, 56S1 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.66 indicates that 56S1 is not in any danger for bankruptcy at the moment.
56S1 has a Altman-Z score of 4.66. This is in the better half of the industry: 56S1 outperforms 77.27% of its industry peers.
56S1 has a debt to FCF ratio of 6.84. This is a slightly negative value and a sign of low solvency as 56S1 would need 6.84 years to pay back of all of its debts.
56S1 has a Debt to FCF ratio of 6.84. This is comparable to the rest of the industry: 56S1 outperforms 45.45% of its industry peers.
56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
56S1 has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.66 |
ROIC/WACC0.63
WACC9.4%
2.3 Liquidity
A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
56S1's Current ratio of 1.05 is on the low side compared to the rest of the industry. 56S1 is outperformed by 72.73% of its industry peers.
56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
56S1 has a worse Quick ratio (0.50) than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.11%, which is quite impressive.
56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
The Revenue has been growing slightly by 7.72% in the past year.
The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 22.11% on average per year.
The Revenue is expected to grow by 10.12% on average over the next years. This is quite good.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
56S1 is valuated quite expensively with a Price/Earnings ratio of 51.25.
Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than 77.27% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.00. 56S1 is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 41.14, which means the current valuation is very expensive for 56S1.
72.73% of the companies in the same industry are cheaper than 56S1, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.70. 56S1 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.25 | ||
| Fwd PE | 41.14 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 77.27% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as 56S1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.41 | ||
| EV/EBITDA | 29.43 |
4.3 Compensation for Growth
56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1's earnings are expected to grow with 23.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.74
PEG (5Y)12.22
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
With a yearly dividend of 0.33%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is comparable with the industry average which is at 0.48.
With a Dividend Yield of 0.33, 56S1 pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
56S1 pays out 25.41% of its income as dividend. This is a sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.41%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
FRA:56S1 (1/8/2026, 7:00:00 PM)
220.9
-1.9 (-0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.88%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap21.50B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target240.69 (8.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)0.77%
PT rev (3m)0.51%
EPS NQ rev (1m)4.24%
EPS NQ rev (3m)14.4%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)-1.45%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.25 | ||
| Fwd PE | 41.14 | ||
| P/S | 7.3 | ||
| P/FCF | 57.41 | ||
| P/OCF | 29.43 | ||
| P/B | 5.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.43 |
EPS(TTM)4.31
EY1.95%
EPS(NY)5.37
Fwd EY2.43%
FCF(TTM)3.85
FCFY1.74%
OCF(TTM)7.51
OCFY3.4%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.74
PEG (5Y)12.22
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.66 |
F-Score8
WACC9.4%
ROIC/WACC0.63
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y27.7%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 51.25 and the Price/Book (PB) ratio is 5.33.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.